|
1
|
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
|
Lancet
|
2005
|
13.18
|
|
2
|
Publication bias: the case for an international registry of clinical trials.
|
J Clin Oncol
|
1986
|
12.14
|
|
3
|
Publication bias: evidence of delayed publication in a cohort study of clinical research projects.
|
BMJ
|
1997
|
9.69
|
|
4
|
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
|
Lancet
|
2007
|
6.82
|
|
5
|
Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer.
|
Br Med J (Clin Res Ed)
|
1986
|
3.52
|
|
6
|
Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.
|
JAMA
|
1997
|
3.51
|
|
7
|
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer.
|
Cancer Treat Rev
|
2000
|
2.78
|
|
8
|
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.
|
J Clin Oncol
|
1989
|
2.57
|
|
9
|
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction.
|
Eur Heart J
|
2002
|
2.49
|
|
10
|
Pravastatin therapy and the risk of stroke.
|
N Engl J Med
|
2000
|
2.46
|
|
11
|
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators.
|
Circulation
|
1996
|
2.03
|
|
12
|
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.
|
Diabetologia
|
2010
|
1.88
|
|
13
|
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
|
Circulation
|
1996
|
1.87
|
|
14
|
Confronting publication bias: a cohort design for meta-analysis.
|
Stat Med
|
1987
|
1.56
|
|
15
|
Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.
|
Lancet
|
2000
|
1.56
|
|
16
|
Quality adjusted survival analysis.
|
Stat Med
|
1990
|
1.48
|
|
17
|
Dynamic balanced randomization for clinical trials.
|
Stat Med
|
1993
|
1.44
|
|
18
|
Quality of life six months after myocardial infarction treated with thrombolytic therapy. AUS-TASK Group. Australian arm of International tPA/SK Mortality Trial.
|
Med J Aust
|
1994
|
1.43
|
|
19
|
Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?
|
Ann Oncol
|
2005
|
1.35
|
|
20
|
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
|
Ann Oncol
|
2011
|
1.21
|
|
21
|
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
|
JAMA
|
1995
|
1.21
|
|
22
|
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.
|
Circulation
|
1996
|
1.16
|
|
23
|
A systematic review of taxane-containing regimens for metastatic breast cancer.
|
Br J Cancer
|
2005
|
1.15
|
|
24
|
Risk-benefit relationships in cancer clinical trials: the ECOG experience in non-small-cell lung cancer.
|
J Clin Oncol
|
1985
|
1.14
|
|
25
|
Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators.
|
J Am Coll Cardiol
|
2001
|
1.14
|
|
26
|
Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials.
|
Am Heart J
|
2003
|
1.12
|
|
27
|
Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.
|
Lancet
|
2001
|
1.03
|
|
28
|
Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial.
|
Circulation
|
2000
|
1.02
|
|
29
|
Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy.
|
Am J Cardiol
|
1999
|
1.01
|
|
30
|
Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.
|
Ann Oncol
|
2011
|
0.99
|
|
31
|
Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer.
|
J Clin Oncol
|
1985
|
0.99
|
|
32
|
A comparison of standard gamble, time trade-off, and adjusted time trade-off scores.
|
Int J Technol Assess Health Care
|
2000
|
0.97
|
|
33
|
Barriers to participation in randomized clinical trials for early breast cancer among Australian cancer specialists.
|
Aust N Z J Surg
|
1999
|
0.96
|
|
34
|
Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators.
|
Am Heart J
|
1997
|
0.94
|
|
35
|
Treatment selection for cancer patients: application of statistical decision theory to the treatment of advanced ovarian cancer.
|
J Chronic Dis
|
1985
|
0.93
|
|
36
|
Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer.
|
Br J Cancer
|
2006
|
0.90
|
|
37
|
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
|
Br J Cancer
|
2011
|
0.90
|
|
38
|
Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.
|
Br J Cancer
|
2010
|
0.89
|
|
39
|
Activity of mouse macrophages purified by adherence to, and removal from, a plastic surface.
|
J Immunol Methods
|
1979
|
0.89
|
|
40
|
Quality adjusted survival analysis with repeated quality of life measures.
|
Stat Med
|
1998
|
0.89
|
|
41
|
Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group.
|
Ann Oncol
|
1997
|
0.87
|
|
42
|
Role of a non-committed accessory cell in the in vivo suppression of a syngeneic tumour by immune lymphocytes.
|
Immunology
|
1975
|
0.84
|
|
43
|
Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
|
J Clin Oncol
|
1997
|
0.83
|
|
44
|
Prognostic value of performance status and quality-of-life scores during chemotherapy for advanced breast cancer. The Australian New Zealand Breast Cancer Trials Group.
|
J Clin Oncol
|
1993
|
0.81
|
|
45
|
Historical cross-trial comparisons for competing treatments in advanced breast cancer--an empirical analysis of bias.
|
Eur J Cancer
|
2009
|
0.81
|
|
46
|
Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin.
|
Intern Med J
|
2011
|
0.80
|
|
47
|
Combining components of quality of life to increase precision and evaluate trade-offs.
|
Stat Med
|
2001
|
0.80
|
|
48
|
Ultrastructure of an odontogenic myxoma.
|
Oral Surg Oral Med Oral Pathol
|
1975
|
0.80
|
|
49
|
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
|
Ann Oncol
|
2012
|
0.80
|
|
50
|
A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.79
|
|
51
|
Treatment of recurrent spontaneous abortion by immunization with paternal lymphocytes: results of a controlled trial.
|
Am J Reprod Immunol
|
1993
|
0.79
|
|
52
|
Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).
|
J Natl Cancer Inst Monogr
|
1992
|
0.78
|
|
53
|
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.
|
Br J Cancer
|
2011
|
0.77
|
|
54
|
Application of statistical decision theory to treatment choices: implications for the design and analysis of clinical trials.
|
Stat Med
|
1987
|
0.76
|
|
55
|
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
|
J Am Coll Cardiol
|
1998
|
0.76
|
|
56
|
A cardiovascular extension of the Health Measurement Questionnaire.
|
J Epidemiol Community Health
|
1999
|
0.75
|
|
57
|
A randomised cross-over trial of antiemetic therapy for platinum-based chemotherapy. Improved control with an intensive multiagent regimen.
|
Eur J Cancer
|
1993
|
0.75
|
|
58
|
[A case of dental fusion].
|
Rev Asoc Odontol Argent
|
1968
|
0.75
|
|
59
|
[Combined odontoma].
|
Rev Asoc Odontol Argent
|
1967
|
0.75
|
|
60
|
Conservative surgery and radiotherapy as primary treatment for early breast cancer: results of a 10 year experience.
|
Australas Radiol
|
1983
|
0.75
|
|
61
|
Metadiagnosis and clinical decisions.
|
Am J Med
|
1984
|
0.75
|
|
62
|
Effect of combined etiologic factors in experimental periodontal lesions.
|
J Periodontal Res Suppl
|
1969
|
0.75
|
|
63
|
Optically addressed spatial light modulators by MBE-grown nipi MQW structures.
|
Appl Opt
|
1989
|
0.75
|
|
64
|
Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease.
|
Control Clin Trials
|
1997
|
0.75
|
|
65
|
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
|
Ann Oncol
|
2013
|
0.75
|
|
66
|
Intervention with PTCA and CABG following thrombolysis for acute myocardial infarction. Australian data from GUSTO 1 (1991-3) and International Study Group r-TPA-Streptokinase Mortality (1989) trials. Global Utilisation of Streptokinase and Tissue.
|
Aust N Z J Med
|
1998
|
0.75
|
|
67
|
Fabry-Perot multiple-quantum well index modulator.
|
Appl Opt
|
1988
|
0.75
|
|
68
|
Informed consent.
|
Lancet
|
1986
|
0.75
|
|
69
|
Doctors' participation in randomized trials of adjuvant systemic therapy in breast cancer: how does it relate to their recommendations for standard therapy in breast cancer?
|
Breast
|
1999
|
0.75
|
|
70
|
Ultrastructure of chondrosarcoma.
|
Clin Orthop Relat Res
|
1974
|
0.75
|
|
71
|
Ifosfamide combination regimens for soft-tissue sarcoma.
|
Cancer Chemother Pharmacol
|
1993
|
0.75
|
|
72
|
Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2.
|
Eur Heart J
|
2007
|
0.75
|
|
73
|
Patient treatment preference in advanced breast cancer: a randomized cross-over study of doxorubicin and mitozantrone.
|
Eur J Cancer Clin Oncol
|
1987
|
0.75
|
|
74
|
Improving cancer care: transferring clinical research into practice through treatment guidelines.
|
Ann Oncol
|
1990
|
0.75
|
|
75
|
Histometric evaluation of periodontal bone loss in rats. I. The effect of marginal irritation, systemic irradiation and trauma from occlusion.
|
J Periodontal Res
|
1971
|
0.75
|
|
76
|
Optically controlled reflection modulator using GaAs-AlGaAs n-i-p-i/multiple-quantum-well structures.
|
Opt Lett
|
1989
|
0.75
|
|
77
|
Predicting patients' utilities from quality of life items: an improved scoring system for the UBQ-H.
|
Qual Life Res
|
1998
|
0.75
|